The loss-of-function mutations (LOF) in the PCSK9 p.(Tyr142*) and p.(Cys679*) were identified in 2.6% of African–American patients analyzed in the study by Cohen et al. [29] and were associated with a 28% reduction in mean LDL-C and an 88% reduction in coronary heart disease (CHD) risk [29]. This evidence concerns the gene PCSK9 and coronary artery disorder.